Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06057675 · ClinicalTrials.gov registry record · Phase 2
Tranexamic Acid in Nasal Mohs Reconstruction
A Phase 2 study of Skin Cancer Face and Postoperative Bleeding, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06057675: Recruiting Phase 2 study of Skin Cancer Face and Postoperative Bleeding, sponsored by Vanderbilt University Medical Center.
NCT06057675 is a Phase 2 study of Skin Cancer Face and Postoperative Bleeding that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06057675, a Phase 2 study of Skin Cancer Face and Postoperative Bleeding, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.
Primary Outcome
Photos will be taken by a research team member at the first postoperative clinic visit and then analyzed and graded by a blinded reviewer for measures including surgical site bruising and swelling. Surgical site swelling and bruising will be graded on a 4 point scale, with 0 indicating no swelling and bruising and 3 indicating significant swelling and bruising.
Conditions Studied
Interventions
- DRUG Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)
- DRUG Control (1% lidocaine with 1:100,000 epinephrine)
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06057675 shows while recruiting
NCT06057675 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Skin Cancer Face appearing as the primary indexed condition, and to 2 interventions - of which Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine) is the first listed.
NCT06057675 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06057675 about?
NCT06057675 is a clinical study titled "Tranexamic Acid in Nasal Mohs Reconstruction". This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.
What is the current status of trial NCT06057675?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-03-19. Estimated completion is 2026-06.
What conditions does trial NCT06057675 study?
This clinical trial studies the following conditions: Skin Cancer Face, Postoperative Bleeding.
What interventions are being tested in trial NCT06057675?
The interventions under investigation include: Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine) (DRUG), Control (1% lidocaine with 1:100,000 epinephrine) (DRUG).
Who is sponsoring clinical trial NCT06057675?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06057675 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer Face
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06057675's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,264 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI